STO-CSCO Joint Symposium 2017

Continuing to build on the vibrant partnership of STO and CSCO, this symposium will be featured during the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) from September 26 – 30, 2017.

Translated Articles

Read translations of selected articles targeting practice issues relevant to Chinese clinicians.

Browse All Topics

The Oncologist in China

Download a 2-page pdf overview of The Oncologist’s Clinical Trial Results section information.

Video Library

Watch the latest presentations from the STO First Advisory Council: LUNG CANCER: A Grand Challenge for Public Health & Education.

Past Meetings

Welcome to 'The Oncologist' in China

Recent Translated Articles from The Oncologist

Volume 22, Number 3, March 2017

Breast Cancer

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer
Linda T. Vahdat, Rachel Layman, Denise A. Yardley, William Gradishar, Mohamad A. Salkeni, Anil Abraham Joy, Agustin A. Garcia, Patrick Ward, James Khatcheressian, Joseph Sparano, Gladys Rodriguez, Shande Tang, Ling Gao, Rita P. Dalal, John Kauh, Kathy Miller
The Oncologist 2017; 22:245-254; first published on February 20, 2017; doi:10.1634/theoncologist.2016-0265

Gastrointestinal Cancer

项FOLFOX +贝伐珠单抗联合或不联合MET抑制剂Onartuzumab一线治疗转移性结直肠癌患者的II期、随机试验(GO27827
A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer
Johanna C. Bendell, Howard Hochster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace, Joshua J. McFarlane, Mark Kozloff, Daniel Catenacci, Jessie J. Hsu, Stephen P. Hack, David S. Shames, See‐Chun Phan, Hartmut Koeppen, Allen L. Cohn
The Oncologist 2017; 22:264-271; first published on February 16, 2017; doi:10.1634/theoncologist.2016-0223

Volume 22, Number 2, February 2017

Clinical Trial Results

A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer
Min‐Hee Ryu, Baek‐Yeol Ryoo, Tae Won Kim, Sung Bae Kim, Hyeong‐Seok Lim, Kyun‐Seop Bae, Sook Ryun Park, Yeong‐Woo Jo, Hyun Ju Cho, Yoon‐Koo Kang
The Oncologist 2017; 22:129-e8; first published on February 14, 2017; doi:10.1634/theoncologist.2016-0273

Gastrointestinal Cancer

An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation‐Negative Pancreatic Ductal Adenocarcinoma
Yoko Shimada, Takashi Kohno, Hideki Ueno, Yoshinori Ino, Hideyuki Hayashi, Takashi Nakaoku, Yasunari Sakamoto, Shunsuke Kondo, Chigusa Morizane, Kazuaki Shimada, Takuji Okusaka, Nobuyoshi Hiraoka
The Oncologist 2017; 22:158-164; first published on February 6, 2017; doi:10.1634/theoncologist.2016-0194

Lung Cancer

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
Xiaofei Wang, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, Thomas E. Stinchcombe, Jeffrey Crawford, Robert Kratzke, Alex A. Adjei, Hedy L. Kindler, Everett E. Vokes, Herbert Pang
The Oncologist 2017; 22:189-198; first published on February 10, 2017; doi:10.1634/theoncologist.2016-0121

No front page content has been created yet.


The Oncologist and the Society for Translational Oncology (STO) partner with the Chinese Society of Clinical Oncology (中国抗癌协会临床肿瘤学协作专业委员会, CSCO) and the CSCO Foundation (中国临床肿瘤学会基金会) on educational initiatives that address critical health and cancer care issues in China. These efforts serve to foster communication between Chinese physicians and other leaders in oncology practice throughout the world.